New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.
As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the effectiveness of the Marseille’s research network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).
MI will enable the development of original and innovative approaches in cancer immunotherapy, based on these three pillars. New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams’ dynamism and local potential.
Our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.
AMU, IPC, CRCM
Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.
CCI Marseille Provence
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients
AMU, IPC, CRCM
HalioDx is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.